Last Updated on December 30, 2023 by The Health Master
Aurobindo Pharma yesterday said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an Active Pharmaceutical Ingredient (API) manufacturing facility.
The action follows the recent inspection of the facility by the US Food and Drug Administration (USFDA) in August 2021, the drugmaker said in a regulatory filing.
“The company believes that this will not impact the existing business from this facility,” it noted.
The drugmaker stated that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest.
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it noted.
Kerala DCA writes to NPPA to bring Kidney drug under DPCO
Pharma firms to install PNG run boilers to improve Air quality
Full marketing approval sought from DCGI for Covaxin
USFDA gives nod to Glenmark for Nasal Spray to treat allergic..
Narcotic Control Bureau seizes Drugs worth Rs 30 lakh
Big Pharma Companies buying land in Hyderabad
Govt warns against overuse, misuse of COVID medicines
BIS notifies new standard for these Medical Devices
Latest Notifications: Medical Devices
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
